Weekly Investment Analysts’ Ratings Changes for Ironwood Pharmaceuticals (IRWD)

Ironwood Pharmaceuticals (NASDAQ: IRWD) recently received a number of ratings updates from brokerages and research firms:

  • 5/6/2019 – Ironwood Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 5/6/2019 – Ironwood Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock, down previously from $14.00.
  • 5/3/2019 – Ironwood Pharmaceuticals was given a new $13.00 price target on by analysts at Morgan Stanley. They now have a “hold” rating on the stock.
  • 5/2/2019 – Ironwood Pharmaceuticals was given a new $20.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 4/30/2019 – Ironwood Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 4/16/2019 – Ironwood Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 4/16/2019 – Ironwood Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $13.00 price target on the stock. According to Zacks, “Ironwood’s sole marketed product Linzess has performed encouragingly on the back of strong demand and expansion in new patient population and geographic regions. The company remains focused on further label expansions of the drug. Meanwhile, the company’s separation into two companies is anticipated to increase operational performance and strategic flexibility. The company’s termination of the license agreement with AstraZeneca related to Zurampic and Duzallo reduced operating expenses. However, competition in CIC and IBS-C, Linzess’ target markets is intensifying. Any Linzess-related pipeline/regulatory setbacks will weigh heavily on the stock as the rest of its pipeline is mostly mid-stage in nature. Shares have underperformed the industry in the past six months. Earnings estimates have remained stable ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in the recent quarters.”
  • 3/27/2019 – Ironwood Pharmaceuticals was upgraded by analysts at Morgan Stanley from an “underweight” rating to an “equal” rating. They now have a $14.00 price target on the stock, up previously from $11.00.
  • 3/22/2019 – Ironwood Pharmaceuticals was given a new $16.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.

NASDAQ:IRWD traded up $0.15 on Thursday, hitting $9.95. The stock had a trading volume of 60,600 shares, compared to its average volume of 1,498,202. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -10.47 and a beta of 1.89. Ironwood Pharmaceuticals, Inc. has a 1 year low of $9.07 and a 1 year high of $21.20.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.10). The business had revenue of $68.73 million for the quarter, compared to analysts’ expectations of $81.93 million. The business’s revenue was down .6% on a year-over-year basis. During the same period last year, the business posted ($0.25) EPS. Analysts expect that Ironwood Pharmaceuticals, Inc. will post -0.12 earnings per share for the current year.

In other news, Director Lawrence S. Olanoff sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $14.41, for a total transaction of $28,820.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Gina Consylman sold 5,677 shares of the firm’s stock in a transaction that occurred on Thursday, February 21st. The stock was sold at an average price of $14.31, for a total transaction of $81,237.87. Following the sale, the chief financial officer now owns 168,543 shares of the company’s stock, valued at approximately $2,411,850.33. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 288,376 shares of company stock valued at $3,822,783. 5.90% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of IRWD. CWM LLC purchased a new position in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $31,000. CWM Advisors LLC purchased a new position in Ironwood Pharmaceuticals in the 1st quarter valued at approximately $154,000. First Manhattan Co. purchased a new position in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $133,000. Gotham Asset Management LLC purchased a new position in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $135,000. Finally, NumerixS Investment Technologies Inc purchased a new position in Ironwood Pharmaceuticals in the 1st quarter valued at approximately $190,000. Institutional investors own 97.04% of the company’s stock.

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Recommended Story: What is a Reverse Stock Split?

Receive News & Ratings for Ironwood Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply